Nestle Sees Obesity Drugs Raising Demand for Nutrition Products
This article is for subscribers only.
Nestle SA Chief Executive Officer Mark Schneider said GLP-1 obesity drugs like Wegovy will probably increase demand for a range of food products that can help avoid nutrient deficiencies.
The company is well-prepared to help users of such treatments with a portfolio that already has annual sales of 1.5 billion Swiss francs ($1.7 billion) including products such as Vital Performance Protein to preserve muscle mass and Garden of Life probiotics to improve gastrointestinal health.